Last reviewed · How we verify
Stroke prevention
Approved treatments
- Xarelto · University Hospital, Montpellier
- Xarelto · Johnson & Johnson
Selective FXa inhibitor that decreases thrombin generation without requiring cofactors.
Clinical guidelines
- FDA label — 1L
To reduce the risk of stroke in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. - FDA label — 1L
To reduce the risk of stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. - FDA label — 1L
To reduce the risk of stroke in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. - FDA label — 1L
To reduce the risk of stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Stroke prevention patent landscape — cliff calendar, originator estates, attackable patents
- Stroke prevention treatment landscape brief
- Stroke prevention treatment updates RSS
Frequently asked questions about Stroke prevention
What drugs treat Stroke prevention?
Tracked treatments include Xarelto.
What is the treatment for Stroke prevention?
Standard treatment for Stroke prevention includes Xarelto. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Stroke prevention?
FDA label publishes guidelines for Stroke prevention. 4 guideline references tracked.
Related
- Treatment landscape: Stroke prevention patent cliff · Stroke prevention CI report
- Treatment: Xarelto · University Hospital, Montpellier
- Treatment: Xarelto · Johnson & Johnson
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing